HYDERABAD, India--(BUSINESS WIRE)--GVK Biosciences (GVK BIO), Asia’s leading drug discovery research and development CRO announced today that it has entered into a collaboration agreement with U.S. based Endo Pharmaceuticals focused on discovering novel small molecules targeting an exciting protein. Under this agreement GVK BIO will use its discovery expertise to deliver a clinical candidate and Endo will develop and commercialize the product arising out of this collaboration. This collaboration arose out of a newly launched concept at GVK BIO named Early Discovery Assets (EDA™).
